Unlike general health products stocked in every health store, CJC-1295 is distributed via a specialist research supply market that Tria residents navigate through international suppliers. What this means for Tria researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those evaluation tools are available to every researcher. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to verify vendor quality systematically — the standards covered in this guide work regardless of your location.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Tria studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
The first step for any Tria researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — search results alone are too heavily influenced by marketing spend. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Tria
COA-verified · International tracking · Research grade
All use of CJC-1295 in Tria or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should follow research laboratory protocols. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and confirm they fall within appropriate thresholds. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
